The authors developed a long-acting recycling antibody against IL-8 called AMY109 which objectively reduced inflammation and fibrosis associated with disease progression, said Dr
Month 1 Avg 2% starting weight loss, possible side effects, lower appetite Month 2 Avg 4% starting weight loss, side effects may return as dose goes up, even lower appetite Month 3 Avg 6% starting weight loss, new routine in place, may notice more energy Month 4 Avg 8% starting weight loss, maintenance dose confirmed, focus on long-term success Month 6 Avg 10% starting weight loss, progress may slow but keeping up your routine helps Month 15 Avg 17% starting weight loss, nearing or at your goal weight, focus shifts to maintenance Not everyone has the same experience on weight loss treatment
Neuroprotective agents can prevent and/or modify the course of neurological disorders
Statistical Analysis All statistical results were conducted using Statistical Analysis System 9.4 version (SAS Institute Inc., Cary, NC, USA)
